AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

BACKGROUND: Among patients with non-metastatic pancreatic cancer, 80% have high-risk, borderline resectable or locally advanced cancer, with a 5-year overall survival of 12%. MASTERPLAN evaluates the safety and activity of stereotactic body radiotherapy (SBRT) in addition to chemotherapy in these pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Oar, Andrew, Lee, Mark, Le, Hien, Wilson, Kate, Aiken, Chris, Chantrill, Lorraine, Simes, John, Nguyen, Nam, Barbour, Andrew, Samra, Jaswinder, Sjoquist, Katrin M., Moore, Alisha, Espinoza, David, Gebski, Val, Yip, Sonia, Chu, Julie, Kneebone, Andrew, Goldstein, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377976/
https://www.ncbi.nlm.nih.gov/pubmed/34412605
http://dx.doi.org/10.1186/s12885-021-08666-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377976/
https://www.ncbi.nlm.nih.gov/pubmed/34412605
http://dx.doi.org/10.1186/s12885-021-08666-y

Ejemplares similares